Innate Pharma provides update on Silicon Valley Bank exposure
Number of shares and voting rights of Innate Pharma as of February 1, 2023
Innate Pharma to participate in upcoming investor conferences
Innate Pharma announces HSR clearance regarding expansion of its collaboration with Sanofi on NK cell engagers
Innate Pharma announces publication of preclinical data with a trifunctional NK cell engager in acute myeloid leukemia in Nature Biotechnology
Sanofi and Innate Pharma expand collaboration for Natural Killer cell therapeutics in oncology
Innate Pharma presents data from ongoing Phase 2 TELLOMAK trial demonstrating clinical activity of lacutamab in advanced Sézary syndrome at ASH 2022
Number of shares and voting rights of Innate Pharma as of December 1, 2022
Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022
Innate Pharma Reports Third Quarter Financial Results
